



PRESS RELEASE
December 4th, 2017

Allegra Therapeutics Announces New Staged Financing Deal to Take the Company Through to End of Phase 3

*Funding supports clinical development up to registration of Allegra's novel antibiotic
to treat resistant Gram-negative bacterial infections in hospitals*

Lörrach, Germany and Saint Louis, France – Allegra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drug-resistant bacterial infections, announces today the initial closing of a staged financing deal designed to complete Phase 3 for Allegra's lead drug development candidate, AAI101. The round was led by new investor, Xeraya Capital. New investor BioMedPartners also participated in the first stage of the financing, which raised €9 million.

The proceeds will fund development of Allegra's novel Extended Spectrum β -lactamase inhibitor, AAI101, which is designed to treat drug-resistant Gram-negative bacterial infections. AAI101 is delivered in combination with the powerful 4th generation cephalosporin antibiotic, cefepime.

The combination of cefepime/AAI101 is in Phase 2 clinical development. The combination is designed for use as broad-spectrum antibacterial therapy to treat hospitalized patients who contract serious infections caused by Gram-negative bacteria, often proven or suspected to express certain resistance mechanisms, particularly extended-spectrum β -lactamases (ESBLs).

The Centers for Disease Control and Prevention [CDC] have estimated¹ that in the U.S. alone at least 2 million people each year acquire serious infections due to drug-resistant bacteria.

Jason Rushton, Partner at Xeraya Capital will join Allegra's Board of Directors. Jason commented, "Allegra is focused to combat serious Gram-negative antibacterial resistance, one of the most widespread and fastest-growing public health concerns of this decade. Allegra's lead product is a compelling approach to address the

¹ Centers for Disease Control and Prevention, U.S. Department of Health and Human Services
Antibiotic Resistance Threats in the United States, 2013



problem and the Company continues to benefit from considerable support from its current investors, external experts and key regulatory agencies.”

Thomas Moeller of BioMedPartners also joins Allegra’s Board of Directors as observer.

Nicholas Benedict, Allegra’s Chief Executive Officer, added, “We are delighted with this investment from Xeraya and BioMed. Their expertise and support will complement the existing investor syndicate and will help drive our Company into the next stage of development. This staged financing deal is a milestone for Allecra and paves the way to the end of the Phase 3 trial with Allecra’s lead product.”

- Ends -

For further information please contact

Allecra Therapeutics GmbH

Nicholas Benedict

+41 79 592 2005

info@allecra.com

About Allecra Therapeutics

Allecra is a biopharmaceutical company established in 2013 in the European BioValley Life Sciences cluster located in the Upper Rhine valley encompassing northwest Switzerland, southwest Germany and the Alsace Region of France. Allecra is focused on the development of novel treatments to combat multi drug-resistant Gram-negative bacterial infections. Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections may otherwise be inadequately treated. Allecra is supported by existing investors Forbion Capital Partners, Delos Capital, Edmond de Rothschild Investment Partners, EMBL Ventures and Nicholas Benedict. Allecra’s wholly-owned French subsidiary is a beneficiary of financial support from the French public bank Bpifrance and from the Région Alsace. For more information on Allecra please visit www.allecra.com or email info@allecra.com.

About Xeraya Capital

Xeraya Capital is a venture capital firm focused exclusively on life science investments. From its base in Malaysia, Xeraya's investment activities span the globe



with current portfolio investments in the US, Europe and Asia. For further information please visit www.xeraya.com.

About BioMedPartners

Based in Basel, BioMedPartners is a leading, independent European venture capital firm that acts frequently as lead- or co-lead investor providing private equity to early- to mid-stage life sciences companies. Since 2003, BioMedPartners has invested in several highly innovative companies, of which 17 have already either successfully been acquired by leading biopharma companies or have completed an IPO. With more than CHF 320 million in capital under management and a strong team of experienced industry experts as well as an extensive scientific network, BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe. In February 2017, the company announced the first closing of BioMedInvest III, their third equity venture capital fund with a target size of CHF 120-150 million and a final closing in Q1 2018. For further information please visit www.biomedvc.com.